2,049 results on '"sevelamer"'
Search Results
2. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)
3. Clinical Characteristics, Therapeutic Options, and Outcomes in Hyperphosphatemic Tumoral Calcinosis: A Systematic Review.
4. A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
5. Correction of hyperphosphatemia in a patient with end-stage chronic kidney disease and a complex case of anemia. A clinical case
6. Sevelamer Improves Vascular Stiffness and Decreases Serum Uric Acid Levels in Patients Ongoing Hemodialysis.
7. Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (PTN_POPS)
8. Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
9. A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
10. FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
11. Elucidating the glucose‐lowering effect of the bile acid sequestrant sevelamer.
12. Association of Sevelamer Initiation with Gastrointestinal Bleeding Hospitalization in Individuals Requiring Hemodialysis.
13. A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP (NORMALIZE)
14. Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
15. Effect of sevelamer on serum phosphorus levels in chronic kidney disease and hemodialysis patients; a systematic review and meta-analysis.
16. Sevelamer Use and Mortality in People with Chronic Kidney Disease Stages 4 and 5 Not on Dialysis.
17. Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.
18. A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
19. Effect of sevelamer on serum phosphorus levels in chronic kidney disease and hemodialysis patients; a systematic review and meta-analysis
20. Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China (RECOVER)
21. Canakinumab in addition to phosphate-binding and phosphaturia-inducing therapy were effective in achieving remission in a child with a large familial calcinotic tumour
22. Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
23. Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1) (MicroB1)
24. GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration (SeveX)
25. Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines (CAL-BAL)
26. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet–fed mice
27. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
28. Different Effects of Non-calcium Phosphate Binders on Serum Calcium
29. The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers
30. Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
31. Head to Head Study Against Sevelamer Hydrochloride
32. PA21 Safety and Efficacy in Adult Chinese Subjects
33. Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization
34. Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin
35. Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
36. Potential role of niacin as adjuvant to sevelamer on serum levels of inorganic phosphorus, calcium and calcium-phosphorus product in hemodialysis patients with hyperphosphatemia
37. Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis (SBR759)
38. Sevelamer Use and Mortality in People with Chronic Kidney Disease Stages 4 and 5 Not on Dialysis
39. Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
40. Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2) (MicroB2)
41. Sevelamer Hydrochloride in Peritoneal Dialysis Patients (SERENE)
42. Repurposing of sevelamer as a novel antidote against aluminum phosphide poisoning: An in vivo evaluation
43. Evaluation of the safety and efficacy of transarterial sevelamer embolization in a rabbit liver cancer model: A challenge on the size rule for vascular occlusion
44. Is Sevelamer Carbonate Better Than Calcium Acetate in ControllingChroni Kidney Disease-Mineral Bone Disease in Dialysis Patients.
45. DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
46. Effect of Calcium-based Phosphate Binders Versus Sevelamer on Mortality of Patients with Hemodialysis: A Meta-analysis.
47. Colonic Mass Secondary to Sevelamer-associated Rectal Ulcer
48. Sevelamer for Reducing Endotoxemia and Immune Activation
49. A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
50. A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.